Stelex Introduces Comprehensive Audit Trail Tool for IBM Maximo
Solution Builds on Existing Functionality to Enable Regulated Industries to Maintain Compliance
Bensalem, PA, February 25, 2010 --(PR.com)-- Stelex, a leading provider of enterprise-wide business solutions to regulated industries, is pleased to introduce its Comprehensive Audit Trail (CAT) Solution. An add-on solution developed specifically for IBM’s Enterprise Asset Management solution (Maximo) CAT brings together the history of all changes for a particular record.
CAT enhances Maximo’s audit trail capability and displays the results in a human readable format, accessible directly from the system. CAT enables easy access to the precise information needed for change control. Available for Maximo version 6.2 and higher, CAT helps regulated companies maintain FDA 21 CFR Part 11 compliance.
“CAT was originally developed for global pharmaceutical manufacturers to enhance the traceability functions within Maximo” said Tony Kashani, president of Stelex. “Product feedback was extremely positive with users sighting ease of use, enhanced access to audit data and ability to utilize the solution for trouble shooting purposes.”
Changes contained in the eRec and Esig entries are shown in one convenient screen tab within the Maximo application. The solution offers greater visibility, accessibility and traceability for change control.
CAT was presented February 21-24, 2010 at the IBM PULSE Conference in Las Vegas, NV.
About Stelex
For over twenty years, Stelex has provided enterprise-wide business solutions to regulated industries such as life sciences, manufacturing, transportation, energy and more. The firm offers a comprehensive suite of technology, validation, regulatory and business solutions. Learn more about Stelex at http://www.stelex.com.
Stelex is a subsidiary of GE Healthcare (NYSE: GE).
All statements in this press release other than historical statements constitute Forward Looking Statements under the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements as a result of a variety of factors, including but not limited to the changes in regulatory requirements in the United States and elsewhere, timing and effectiveness of changes to marketing and sales plans, programs and strategies; market conditions; customer response; technological change; and competition and other factors referred to by Vital Signs in its Annual Report on Form 10-K for the year ended September 30, 2009 and other reports filed with the Securities and Exchange Commission.
###
CAT enhances Maximo’s audit trail capability and displays the results in a human readable format, accessible directly from the system. CAT enables easy access to the precise information needed for change control. Available for Maximo version 6.2 and higher, CAT helps regulated companies maintain FDA 21 CFR Part 11 compliance.
“CAT was originally developed for global pharmaceutical manufacturers to enhance the traceability functions within Maximo” said Tony Kashani, president of Stelex. “Product feedback was extremely positive with users sighting ease of use, enhanced access to audit data and ability to utilize the solution for trouble shooting purposes.”
Changes contained in the eRec and Esig entries are shown in one convenient screen tab within the Maximo application. The solution offers greater visibility, accessibility and traceability for change control.
CAT was presented February 21-24, 2010 at the IBM PULSE Conference in Las Vegas, NV.
About Stelex
For over twenty years, Stelex has provided enterprise-wide business solutions to regulated industries such as life sciences, manufacturing, transportation, energy and more. The firm offers a comprehensive suite of technology, validation, regulatory and business solutions. Learn more about Stelex at http://www.stelex.com.
Stelex is a subsidiary of GE Healthcare (NYSE: GE).
All statements in this press release other than historical statements constitute Forward Looking Statements under the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements as a result of a variety of factors, including but not limited to the changes in regulatory requirements in the United States and elsewhere, timing and effectiveness of changes to marketing and sales plans, programs and strategies; market conditions; customer response; technological change; and competition and other factors referred to by Vital Signs in its Annual Report on Form 10-K for the year ended September 30, 2009 and other reports filed with the Securities and Exchange Commission.
###
Contact
Altitude Marketing
Gwen Hoover
610-421-8601
stelex.com/
Gwen Hoover
610-421-8601
stelex.com/
Contact
Categories